These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36651601)

  • 1. Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials.
    Lim LSH; Lokku A; Pullenayegum E; Ringold S
    Arthritis Care Res (Hoboken); 2023 Jun; 75(6):1238-1249. PubMed ID: 36651601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.
    Golhen K; Winskill C; Yeh C; Zhang N; Welzel T; Pfister M
    Front Pediatr; 2022; 10():909118. PubMed ID: 35799700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
    Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
    Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Horneff G; Huppertz HI; Job-Deslandre C; Loy A; Minden K; Punaro M; Nunez AF; Sigal LH; Block AJ; Nys M; Martini A; Giannini EH;
    Arthritis Rheum; 2010 Jun; 62(6):1792-802. PubMed ID: 20191582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a composite disease activity score for juvenile idiopathic arthritis.
    Consolaro A; Ruperto N; Bazso A; Pistorio A; Magni-Manzoni S; Filocamo G; Malattia C; Viola S; Martini A; Ravelli A;
    Arthritis Rheum; 2009 May; 61(5):658-66. PubMed ID: 19405003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
    Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
    Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
    Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
    Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
    Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry.
    Becker I; Horneff G
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):552-560. PubMed ID: 27390133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
    Vojinovic J; Damjanov N; D'Urzo C; Furlan A; Susic G; Pasic S; Iagaru N; Stefan M; Dinarello CA
    Arthritis Rheum; 2011 May; 63(5):1452-8. PubMed ID: 21538322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study.
    Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM
    Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
    Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate.
    Chickermane PR; Khubchandani RP
    Clin Exp Rheumatol; 2015; 33(2):287-92. PubMed ID: 25738527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication burden in young adults with juvenile idiopathic arthritis: data from a multicentre observational study.
    Montag LJ; Horneff G; Hoff P; Klein A; Kallinich T; Foeldvari I; Seipelt E; Tatsis S; Peer Aries MD; Niewerth M; Klotsche J; Minden K
    RMD Open; 2022 Oct; 8(2):. PubMed ID: 36283758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.
    van Rossum MA; van Soesbergen RM; Boers M; Zwinderman AH; Fiselier TJ; Franssen MJ; ten Cate R; van Suijlekom-Smit LW; Wulffraat NM; van Luijk WH; Oostveen JC; Kuis W; Dijkmans BA;
    Ann Rheum Dis; 2007 Nov; 66(11):1518-24. PubMed ID: 17491099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.